TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16390568

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study: 15023611

Group type: EXPERIMENTAL
Intervention: 500 mg/d vitamin C
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 1000 mg/d grape-seed polyphenols
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and polyphenols
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 69
Study: 10731538

Group type: EXPERIMENTAL
Intervention: E(2) supplementation during the luteal phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (progestin supplementation without E(2))
Number of subjects: 0
Study: 9190279

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Plating
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 272
Study: 1491345

Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of moxisylyte (two formulations)
Number of subjects: 12
Study: 3085257

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (single high dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30234925

Group type: EXPERIMENTAL
Intervention: single‐bolus
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: intermittent‐boluses
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: short‐infusion
Number of subjects: 270
Study: 26470783

Group type: EXPERIMENTAL
Intervention: Exenatide (7.5 μg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 24794277

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 623

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 623
Study: 23383459

Group type: EXPERIMENTAL
Intervention: Acupuncture group (scalp acupoint Dingnie Qianxiexian (MS 6) and body acupoints Neiguan (PC 6), Jianyu (LI 15), Sanyinjiao (SP 6), treated once daily for 20 days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (routine neurological therapies only)
Number of subjects: 110
Study: 20190281

Group type: EXPERIMENTAL
Intervention: VIA-2291 (25, 50, or 100 mg daily for 12 weeks)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: VIA-2291
Number of subjects: 191
Study: 18525134

Group type: EXPERIMENTAL
Intervention: Memory Power
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 16543162

Group type: EXPERIMENTAL
Intervention: Novare Enclose PAD
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard aortic side-clamp technique
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197
Study: 14652381

Group type: EXPERIMENTAL
Intervention: Dietary intervention (plant food-based diet with intensive counseling)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 10822428

Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 24 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 8 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 125 mg L-dopa every 8 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 250 mg L-dopa every 24 hours (3 months prolonged treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 125 mg L-dopa every 8 hours (3 months prolonged treatment)
Number of subjects: 24
Study: 8798095

Group type: EXPERIMENTAL
Intervention: 1 day catheterization
Number of subjects: 91

Group type: COMPARATOR
Intervention: 3 days catheterization
Number of subjects: 91
Study: 1633900

Group type: EXPERIMENTAL
Intervention: Zygote intrafallopian transfer (ZIFT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: In vitro fertilization and embryo transfer (IVF‐ET)
Number of subjects: 157
Study: 6487442

Group type: EXPERIMENTAL
Intervention: Halothane in oxygen
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fentanyl plus nitrous oxide in oxygen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enflurane in oxygen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Isoflurane in oxygen
Number of subjects: 51
Study: 31165888

Group type: EXPERIMENTAL
Intervention: Conditioning
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Congruent Conditioning
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Incongruent Conditioning
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Verbal Suggestion
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 30200068

Group type: EXPERIMENTAL
Intervention: 80‐kV group with automatic tube current modulation and AIDR 3D algorithm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 80‐kV group
Number of subjects: 128

Group type: COMPARATOR
Intervention: 100‐kV group
Number of subjects: 128
Study: 26156950

Group type: EXPERIMENTAL
Intervention: Controlled diet for 4 days followed by ad libitum intake on day 5
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ad libitum intake on day 5
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Greater fiber intake
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Percent of energy from saturated fat
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Higher percent of energy from sugar
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Higher percent of energy from other carbohydrates not considered sugar or fiber
Number of subjects: 26
Study: 24139977

Group type: EXPERIMENTAL
Intervention: Adapted cognitive behaviour therapy (CBT-HA group)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444

Group type: COMPARATOR
Intervention: Adapted cognitive behaviour therapy (CBT-HA group) and Standard care
Number of subjects: 444
Study: 23759035

Group type: EXPERIMENTAL
Intervention: Guided online sleep training based on Cognitive Behavioral Therapy for insomnia.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist-control condition.
Number of subjects: 128
Study: 20116286

Group type: EXPERIMENTAL
Intervention: Chemoembolization
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-chemoembolization (Control)
Number of subjects: 28
Study: 18670242

Group type: EXPERIMENTAL
Intervention: Caffeine intake (highest quartile)
Number of subjects: 413
Study: 17127828

Group type: EXPERIMENTAL
Intervention: Lamivudine at 100 mg/daily orally for 52 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lamivudine at 100 mg/die plus alpha-interferon at 6 MU subcutaneously three times weekly for 52 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination therapy (lamivudine plus alpha-interferon) for 40 weeks after pre-treatment with lamivudine for 12 weeks
Number of subjects: 59
Study: 12623499

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0
Study: 11908357

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength Toothpaste (5.0% potassium nitrate and 0.454% stannous fluoride in a silica base)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sensodyne Fresh Mint Toothpaste (5.0% potassium nitrate and 0.243% sodium fluoride in a silica base)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Colgate Winterfresh Gel (0.243% sodium fluoride in a silica base)
Number of subjects: 121
Study: 8999672

Group type: EXPERIMENTAL
Intervention: Russian hepatitis B Combiotech vaccine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombivax‐HB vaccine (10 mg)
Number of subjects: 0
Study: 1443845

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride (two sprays, 15 minutes before therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (control group, two sprays, 15 minutes before therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (control group)
Number of subjects: 60
Study: 2861880

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 17354

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17354
Study: 29440132

Group type: EXPERIMENTAL
Intervention: Low threshold (LT) intervention (ventricular index (VI) >p97 and anterior horn width (AHW) >6 mm)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Higher threshold (HT) intervention (VI>p97+4 mm and AHW >10 mm)
Number of subjects: 126
Study: 30945606

Group type: EXPERIMENTAL
Intervention: Narrow cuff
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Wide cuff
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher applied pressure
Number of subjects: 183

Group type: COMPARATOR
Intervention: Lower applied pressure
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Sets 2, 3, and 4
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Echo intensity measurement
Number of subjects: 183
Study: 27935660

Group type: EXPERIMENTAL
Intervention: 0.12% CHX mouthrinses (Group II) used twice a week for 4 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo mouthrinses (Group I)
Number of subjects: 34
Study: 25971288

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban (LDE)
Number of subjects: 2492

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2492

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban (HDE)
Number of subjects: 2492
Study: 24186056

Group type: EXPERIMENTAL
Intervention: Harmonic dissection devices (HDDs)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 139
Study: 21764407

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 120 U
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 240 U
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 19052155

Group type: EXPERIMENTAL
Intervention: Media literacy education
Number of subjects: 531
Study: 16689041

Group type: EXPERIMENTAL
Intervention: Pill counts for psychotropic medications
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-report and informant ratings
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lower medication adherence
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Medication Management Administration Assessment (MMAA) role-play
Number of subjects: 72
Study: 15160510

Group type: EXPERIMENTAL
Intervention: Meropenem plus amikacin (20 mg/kg every 8 h plus 15 mg/kg/d in 2 divided doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam plus netilmicin (100 mg/4 mg/kg every 8 h plus 7 mg/kg every 24 h)
Number of subjects: 33
Study: 11406794

Group type: EXPERIMENTAL
Intervention: Cement applied over the posts only (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cement introduced into the root canals with a spiral filler and applied over the posts (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cement injected into the root canals and then applied over the posts (Group C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cement injected into the root canals and a spiral used to spread it into the root canals, and cement applied over the posts (Group D)
Number of subjects: 24
Study: 9001768

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension (LE), q.i.d. for 6 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (loteprednol etabonate vehicle), q.i.d. for 6 weeks
Number of subjects: 220
Study: 8105785

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (one week's treatment)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Budesonide (two weeks' treatment)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (one week's treatment)
Number of subjects: 52
Study: 3610426

Group type: EXPERIMENTAL
Intervention: Demonstration only
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Demonstration-simulation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non intervention (control)
Number of subjects: 75
Study: 31978740

Group type: EXPERIMENTAL
Intervention: Behavioral change intervention on handwashing, exclusive breastfeeding before the age of six months, and awareness on diarrhea prevention methods
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Provision of safe and adequate water source combined with household water chlorination, and vaccination for rotavirus
Number of subjects: 826

Group type: COMPARATOR
Intervention: Children less than six months of age
Number of subjects: 826

Group type: COMPARATOR
Intervention: Initiating supplementary feedings before six months of age
Number of subjects: 826

Group type: COMPARATOR
Intervention: Low educational status of mothers
Number of subjects: 826

Group type: COMPARATOR
Intervention: Limited knowledge of mothers about diarrhea
Number of subjects: 826

Group type: COMPARATOR
Intervention: Absence of hand washing among mothers/caregivers at critical times
Number of subjects: 826

Group type: COMPARATOR
Intervention: Sharing residence with domestic animals
Number of subjects: 826

Group type: COMPARATOR
Intervention: Living in semi pastoral areas
Number of subjects: 826

Group type: COMPARATOR
Intervention: Unvaccinated children for rotavirus prevention
Number of subjects: 826

Group type: COMPARATOR
Intervention: Households obtaining water from unimproved sources
Number of subjects: 826

Group type: COMPARATOR
Intervention: Households with unimproved latrine facilities
Number of subjects: 826
Study: 29306452

Group type: EXPERIMENTAL
Intervention: Baseline polyunsaturated phosphatidylcholines (PC)/lysoPC/PC‐plasmalogens and polyunsaturated cholesterol esters (CE)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Baseline monoacylglycerols (MAGs)/diacylglycerols (DAGs) and short triacylglycerols (TAGs)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Baseline phosphatidylethanolamines (PEs) and their 1‐y changes
Number of subjects: 983

Group type: COMPARATOR
Intervention: Mediterranean Diet intervention
Number of subjects: 983
Study: 27566742

Group type: EXPERIMENTAL
Intervention: Deflazacort 0.9 mg/kg/d
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Deflazacort 1.2 mg/kg/d
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 23925646

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 0.25% bupivacaine (100 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intraperitoneal saline
Number of subjects: 104
Study: 23893225

Group type: EXPERIMENTAL
Intervention: Active and passive warming measures as described in ASPAN's guidelines
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 60
Study: 20497992

Group type: EXPERIMENTAL
Intervention: Framingham risk equation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pocock risk equation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dubbo risk equation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk equations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recalibration analysis
Number of subjects: 0
Study: 18701233

Group type: EXPERIMENTAL
Intervention: Single-bedded rooms
Number of subjects: 2

Group type: COMPARATOR
Intervention: Four-bedded rooms
Number of subjects: 2
Study: 16870658

Group type: EXPERIMENTAL
Intervention: OrM3 0.5, 2, 3 or 4 mg orally once daily
Number of subjects: 412

Group type: COMPARATOR
Intervention: Ipratropium bromide 36 mug by inhalation four times daily
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 12882874

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1/HOMA-IR
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: QUICKI or 1/HOMA-IR
Number of subjects: 150
Study: 10791670

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nail insertion
Number of subjects: 94

Group type: COMPARATOR
Intervention: Unreamed intramedullary nail insertion
Number of subjects: 94
Study: 8851905

Group type: EXPERIMENTAL
Intervention: Glucose (18.5% w/v solution)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maize syrup solids (18.5% w/v solution)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sucrose (18.5% w/v solution)
Number of subjects: 9
Study: 1632399

Group type: EXPERIMENTAL
Intervention: Drug therapy (atenolol, dihydroergotamine, domperidone, cafedrine, elastic compression stockings)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and placebo)
Number of subjects: 30
Study: 6760390

Group type: EXPERIMENTAL
Intervention: 400 mg/day of sobrerol for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2.0 g glyceringuaiacol per day for 14 days
Number of subjects: 23
Study: 30855411

Group type: EXPERIMENTAL
Intervention: Suture removal 6 weeks postoperatively
Number of subjects: 82

Group type: COMPARATOR
Intervention: Suture left in place (Control)
Number of subjects: 82
Study: 29912935

Group type: EXPERIMENTAL
Intervention: Egocentric network support for physical activity (PA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Network size, familial ties, contact frequency
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ego-alter dissimilarities in age and running, similarities in walking
Number of subjects: 102
Study: 26813467

Group type: EXPERIMENTAL
Intervention: Prodigest® (ginger and artichoke extract)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prodigest® (two capsules)
Number of subjects: 11
Study: 23751914

Group type: EXPERIMENTAL
Intervention: Gamma neurofeedback
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta neurofeedback
Number of subjects: 20
Study: 18508296

Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 48 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Number of subjects: 200
Study: 15173679

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study: 11318060

Group type: EXPERIMENTAL
Intervention: Participant-paced condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer-paced condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response deadline imposed in Experiment 3
Number of subjects: 0
Study: 9088894

Group type: EXPERIMENTAL
Intervention: 0.1 IE per kg body weight regular insulin (insulin induced hypoglycemia)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1 ml 0.9% sodium chloride (placebo)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.1 IE per kg body weight regular insulin plus glucose 10% (euglycemic hyperinsulinemic glucose clamp)
Number of subjects: 15
Study: 8192109

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HDD) for 48 hours followed by intermediate-dose dexamethasone (IDD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-dose dexamethasone (HDD) followed by no steroids with cranial radiotherapy
Number of subjects: 12
Study: 2855297

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms per treatment, intranasally, three times daily for 5 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 63
Study: 11468426

Group type: EXPERIMENTAL
Intervention: d4T monotherapy for 8 weeks
Number of subjects: 31
Study: 31254201

Group type: EXPERIMENTAL
Intervention: Investigational arm (66.7% of deaths occurred here)
Number of subjects: 23387

Group type: EXPERIMENTAL
Intervention: Anthracycline-taxane-based chemotherapy (51.1% of deaths occurred here)
Number of subjects: 23387

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 23387
Study: 29606226

Group type: EXPERIMENTAL
Intervention: S-Health smartphone application with daily surveys on cravings, affects, triggers, responses to triggers, and social contexts.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Text messages from S-Health (e.g., HIV prevention and other educational materials).
Number of subjects: 75
Study: 27352175

Group type: EXPERIMENTAL
Intervention: C18 (18 mmol/l citrate solution)
Number of subjects: 48

Group type: COMPARATOR
Intervention: C15 (15 mmol/l citrate solution)
Number of subjects: 48
Study: 25001621

Group type: EXPERIMENTAL
Intervention: Sufentanil administered intraoperatively and hydromorphone dosed postoperatively via target-controlled infusion (TCI) and patient-controlled analgesia (PCA) until 8 a.m. on the first postoperative day.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 50
Study: 22157844

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) consisting of four 5 min cycles of lower limb ischaemia and reperfusion
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 55
Study: 19875173

Group type: COMPARATOR
Intervention: Everting sutures (ES) alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Everting sutures with a lateral tarsal strip (ES+LTS)
Number of subjects: 63
Study: 17291336

Group type: EXPERIMENTAL
Intervention: Combined radiocolloid and blue dye technique for SLN biopsy
Number of subjects: 371
Study: 16158800

Group type: EXPERIMENTAL
Intervention: Debridement and short-term usage of antimicrobial agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole dispensed after the first and second annual examinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12008938

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with melagatran and ximelagatran or dalteparin (exact dosage not specified)
Number of subjects: 1600
Study: 10482198

Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0